TAR-200 for Treatment of BCG-Unresponsive, High-Risk NMIBC

Author(s):

An expert discusses how the SunRISe-1 phase 2b trial, presented at the European Society for Medical Oncology 2024 Congress (ESMO 2024), evaluated TAR-200 alone and with cetrelimab in BCG-unresponsive, high-risk non–muscle invasive bladder cancer (NMIBC). TAR-200 monotherapy achieved an 84% complete response rate, with most adverse events being mild to moderate. The combination therapy showed higher rates of severe adverse events. TAR-200 is particularly promising for patient’s ineligible for or refusing radical cystectomy.

EP: 1.Drug Delivery Systems in NMIBC

Now Viewing

EP: 2.TAR-200 for Treatment of BCG-Unresponsive, High-Risk NMIBC

Video content above is prompted by the following:

The results of the SunRISe-1 phase 2b clinical trial, which investigated the use of the TAR-200 delivery system alone vs with cetrelimab, were recently presented at ESMO 2024.
What are your impressions of the safety and efficacy data?
Which patients might be the best candidates for the TAR-200 delivery system based on this data?